EQS-Adhoc: SHOP APOTHEKE EUROPE and GALENICA: Antitrust clearances for joint venture granted
EQS-Ad-hoc: SHOP APOTHEKE EUROPE N.V. / Key word(s): Joint Venture/Capital Increase SHOP APOTHEKE EUROPE and GALENICA: Antitrust clearances for joint venture granted Sevenum, the Netherlands, 11 May 2023 Redcare Pharmacy N.V. (formerly SHOP APOTHEKE EUROPE N.V.) and GALENICA AG announce that they have received clearances from the relevant antitrust authorities for the incorporation of their announced joint venture in the Swiss market (the ""). The antitrust clearances were conditions precedent for the execution of the , under which the business activities of shop-apotheke.ch and Mediservice AG will be merged into a joint company. Following the approval, the will now be closed as planned on short notice, expected to be on 16 May 2023. Furthermore, the capital increase to be carried out as part of the Transaction is expected to be concluded by the end of June 2023 at the latest.
End of Inside Information
11-May-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | SHOP APOTHEKE EUROPE N.V. |
Erik de Rodeweg 11-13 | |
5975 WD Sevenum | |
Netherlands | |
Phone: | 0800 - 200 800 300 |
Fax: | 0800 - 90 70 90 20 |
E-mail: | [email protected] |
Internet: | www.shop-apotheke-europe.com |
ISIN: | NL0012044747, DE000A19Y072 |
WKN: | A2AR94, A19Y07 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1631243 |
End of Announcement | EQS News Service |
|
1631243 11-May-2023 CET/CEST
Shop Apotheke Europe NV Aktie
Einige Buy-Einschätzungen dominieren bei Shop Apotheke Europe NV gegenüber Sell-Einschätzungen.
Ein positives, aber moderates Potenzial für Shop Apotheke Europe NV mit einem Kursziel von 145 € im Vergleich zu 131.0 €.